Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development
11 Luglio 2023 - 2:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer
of critical reagents for the research, discovery, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, today launched the next set of reagents in the
Company’s proprietary product line, AAV-Tek™ Solutions.
Available for purchase starting today is a version of Teknova’s
AAV-Tek AEX Buffer Screening Kit for the AAV8 serotype, along with
a suite of reagents to support the entire gene therapy workflow.
“After we introduced our first proprietary gene therapy product
a few months ago – the AAV-Tek AEX Buffer Screening Kit for AAV2 –
customers encouraged us to create additional solutions to better
support AAV gene therapy developers,” said Stephen Gunstream,
Teknova’s President and Chief Executive Officer. “In a few short
months, our talented team has delivered the AEX Buffer Screening
Kit for AAV8, specifically designed to help gene therapy developers
save months in process development time. We’re also making
available more than 20 additional reagents we’ve identified as key
solutions to support the entire gene therapy workflow. We are
uniquely positioned to address key bioprocessing bottlenecks and
streamline the manufacturing process through a combination of new,
proprietary products and off-the-shelf, proven reagents, as we help
our gene therapy customers seamlessly scale from process
development to clinical production.”
The AAV-Tek AEX Buffer Screening Kit was created to help
streamline the identification of the ideal buffer formulation for
use during AAV downstream processing, specifically during the anion
exchange (AEX) purification step. Developed by Teknova’s Research
and Development team, the kit addresses critical pain points in the
workflow by providing a selection of serotype-specific
equilibration and elution buffers to optimize the separation of
empty and full capsids during polishing. Teknova conducted a robust
design of experiments across multiple AAV serotypes by monitoring
four different critical quality attributes (infectivity, recovery,
purity, and peak separation), to identify the optimal number of
buffers for use across a variety of upstream workflows, transgenes,
and downstream purification platforms.
Teknova is also introducing a suite of 24 high-quality,
off-the-shelf reagents as part of the Company’s AAV-Tek Solutions
product line, including cell lysis solutions, filtration wash
buffers, and capture chromatography reagents. Designed to address
end-to-end upstream and downstream bioprocessing needs, this array
of new solutions – including the AAV-Tek AEX Buffer Screening Kit –
positions Teknova as a single-source partner for gene therapy
developers to help them streamline and scale their end-to-end
biomanufacturing process development and enter the clinic
faster.
Along with the kit for AAV2 launched previously, the AAV-Tek AEX
Buffer Screening Kit for AAV8 is available today for purchase via
phone, email, or online, and is priced at $1,000. Teknova is
continuing to work on additional serotypes – AAV6, AAV9, and AAV5 –
for release later this year.
For more information about the AAV-Tek AEX Buffer Screening Kit
or to purchase it online, visit www.teknova.com/AAV8.
For more information about the suite of AAV gene therapy
workflow solutions or to purchase them online, visit
www.teknova.com/aav-workflow.
ABOUT TEKNOVATeknova makes solutions possible.
Since 1996, Teknova has been innovating the manufacture of critical
reagents for the life sciences industry to accelerate the discovery
and development of novel therapies that will help people live
longer, healthier lives. We offer fully customizable solutions for
every stage of the workflow, supporting industry leaders in cell
and gene therapy, molecular diagnostics, and synthetic biology. Our
fast turnaround of high-quality agar plates, microbial culture
media, buffers and reagents, and water helps our customers scale
seamlessly from RUO to GMP. Headquartered in Hollister, California,
with over 200,000 square feet of state-of-the-art facilities,
Teknova’s modular manufacturing platform was designed by our team
of scientists, engineers, and quality control experts to
efficiently produce the foundational ingredients for the discovery
and commercialization of novel therapies.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024